Dr. Jorge Monge urrea M.D.

Recommended Articles

• Facts About Multiple Myeloma

  Multiple myeloma is a certain form of cancer of the plasma cell, which is part of the immune system. It initiates in the bone marrow, where the blood cells are produced.The immune system is made of variety of cells that fight infections and keep the body healthy. What takes place in bone marrow...

• How is Multiple Myeloma Diagnosed?

  Various tests are conducted for the diagnosis of multiple myeloma since one result of a laboratory test cannot diagnose it alone. A number of factors like the history, complete body check-up, diagnostic test reports and symptoms of the patient are taken into consideration to get a proper diagnosis...

• Overcoming Lymphoma: A South Philly Student's Story

  In April of 2018, 18-year-old Alexis Carine was diagnosed with Hodgkin’s lymphoma (HL), a blood cancer that begins in the lymphatic system. Her diagnosis was stage II HL, a cancer found in two or more lymph node areas, and both are either above or below the diaphragm (the muscle located just...

• Woman Who Battled Lymphoma Three Times Starts Support Group

  Battling cancer is just that - a battle. To make it through once is an incredible feat, but one Virginia Beach woman survived the terrible condition three times. Now, she is starting a support group so other women can have the incredible outcome she had as well.Lynne's storyUnfortunately, most...

• What Specialists Treat Multiple Myeloma?

  If you suffer from multiple myeloma, which a rare form of blood cancer, one of the most crucial decisions you will have to make is choosing a doctor who specializes in multiple myeloma. A hematologist-oncologist is the specialist you need who will manage your cancer throughout the cycle of...

• Breaking News on the Treatment of Follicular Lymphoma

  Reuters, the international news agency out of London, has announced that the FDA has given a new drug “accelerated approval,” for the treatment of follicular lymphoma.The drug, Aliqopa (copanlisib), showed complete or partial shrinkage of tumors in 59% of study participants during drug studies,...